Effect of erythropoietin therapy on serum apolipoprotein A1 levels in patients undergoing chronic peritoneal dialysis

Peritoneal Dialysis International

Volumn 19, Issue 5, 1999, Pages 486-490

  Kagan, Alexander ^a   Haran, Nurit ^a   Leschinsky, Ludmila ^a   Lerner, Zvi ^a   Shuali, Nechama ^a   Rapoport, Jayson ^a  

^a KAPLAN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; LIPID; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CORRELATION FUNCTION; DIABETES MELLITUS; FEMALE; HEMATOCRIT; HUMAN; KIDNEY FAILURE; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL;

EID: 0033402024     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089901900515     Document Type: Article

References (17)

1. Nissenson AR, Korbet S, Faber M, Burkart J, Gentile D, Hamburger R, et al. Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol 1995; 5:1517-29.
2. Barany P, Clyne N, Hylander B, Johansson A-C, Simonsen O, Larsson R, et al. Subcutaneous epoetin beta in renal anemia: an open multicenter dose titration study of patients on continuous peritoneal dialysis. Perit Dial Int 1995; 15:54-60.
3. Mat O, Stolear J-C, Georges B. Blood lipid profile in hemodialysis patients treated with human erythropoietin. Nephron 1992; 60:236-7.
4. Viron B, Donsimori R, Michel C, Khayat R-Al, Mignon F. Effect of recombinant human erythropoietin on nutritional status and plasma lipids in uremie patients. Nephron 1992; 60:249.
5. Pollock CA, Wyndham R, Collett PV, Elder G, Field MJ, Kalowski S, et al. Effects of erythropoietin therapy on the lipid profile in end-stage renal failure. Kidney Int 1994; 45:897-902.
6. Allegra V, Martimbianco L, Mengozzi G, Vasile A. Erythropoietin and cardiovascular risk. Blood Purif 1995; 13:301-13.
7. Manitius J, Szolkiewicz M, Mysliwska J, Zorena K, Mysliwski A, Jakubowski Z, et al. Influence of "non-hematological" doses of erythropoietin on lipid-carbohydrate metabolism and life quality in hemodialysis patients. Nephron 1995; 69:363-4.
8. Cengiz K. Does recombinant human erythropoietin affect plasma lipids in hemodialysis patients? Nephron 1996; 74:731-2.
9. Mak RHK. Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia. J Pediatr 1996; 129:97-104.
10. Allegra V, Martimbianco L, Vasile A. Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet. Nephrol Dial Transplant 1997; 12:924-32.
11. Kagan A, Elimalech E, Lerner Z, Fink A, Bar-Khayim Y. Residual renal function affects lipid profile in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 1997; 17:243-9.
12. Kratz A, Lewandrowski KB. Normal reference laboratory values. N Engl J Med 1998; 339:1063-72.
13. Kronenberg F, Trenkwalder E, Kronenberg MF, Konig P, Utermann G, Dieplinger H. Influence of hematocrit on the measurement of lipoproteins demonstrated by the example of lipoprotein(a). Kidney Int. 1998; 54:1385-9.
14. Borissova AM, Djambazova A, Todorov K, Dakovska L, Tankova T, Kirilov G. Effect of erythropoietin on the metabolic state and peripheral insulin sensitivity in diabetic patients on hemodialysis. Nephrol Dial Transplant 1993; 8:93-5.
15. Mak RHK, De Fronzo RA. Glucose and insulin metabolism in uremia. Nephron 1992; 61:377-82.
16. Burkart JM, Freedman BI, Rocco MV. The effect of increasing hematocrit on peritoneal transport kinetics. J Am Soc Nephrol 1994; 4:1726-32.
17. Garfagnini A, Devoto G, Rosseli P, Boggiano P, Venturini M. Relationship between HDL-cholesterol and apolipoprotein A1 and severity of coronary artery disease. Eur Heart J 1995; 16:465-70.